PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas

Endocrine

Volumn 42, Issue 2, 2012, Pages 285-291

  Rubinfeld, Hadara ^a   Shimon, Ilan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

ERK; mTOR; Non functioning pituitary adenomas; PI3K; Somatostatin

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; BIM 23A760; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; GEFITINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NVP AEW 541; OCTREOTIDE; PASIREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAF PROTEIN; RAPAMYCIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

AKT GENE; ANTIPROLIFERATIVE ACTIVITY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; DRUG CYTOTOXICITY; DRUG EFFICACY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 8 GENE; ERK GENE; GENE EXPRESSION PROFILING; GROWTH HORMONE SECRETING ADENOMA; HEADACHE; HUMAN; HYPOPITUITARISM; MEK GENE; MTOR GENE; MULTIPLE ENDOCRINE NEOPLASIA; NONFUNCTIONING PITUITARY ADENOMA; NONHUMAN; PHOSPHATASE AND TENSIN HOMOLOG DELETED ON CHROMOSOME 10 GENE; PI3K GENE; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAF GENE; REVIEW; SIGNAL TRANSDUCTION; VISUAL FIELD DEFECT; ZAC1 GENE;

EID: 84867396558     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9682-3     Document Type: Review

References (68)

1. F. Roelfsema, N.R. Biermasz, A.M. Pereira, Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15, 71-83 (2011)
2. A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, S. Savastano, Medical therapy for clinically non-functioning pituitary adenomas. Endocr. Relat. Cancer 15(4), 905-915 (2008)
3. M.A. Tichomirowa, A.F. Daly, A. Beckers, Treatment of pituitary tumors: somatostatin. Endocrine 28(1), 93-100 (2005)
4. A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, B. Dipl, D. Mills, L.R. Salgado, B.M. Biller, A 12-month phase 3 study of pasireotide in Cushing's disease. N. Engl. J. Med. 366(10), 914-924 (2012)
5. M. Boscaro, W.H. Ludlam, B. Atkinson, J.E. Glusman, S. Petersenn, M. Reincke, P. Snyder, A. Tabarin, B.M. Biller, J. Findling, S. Melmed, C.H. Darby, K. Hu, Y. Wang, P.U. Freda, A.B. Grossman, L.A. Frohman, J. Bertherat, Treatment of pituitary- dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J. Clin. Endocrinol. Metab. 94(1), 115-122 (2009)
6. M.S. Elston, A.J. Gill, J.V. Conaglen, A. Clarkson, J.M. Shaw, A.J. Law, R.J. Cook, N.S. Little, R.J. Clifton-Bligh, B.G. Robinson, K.L. McDonald, Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 149(3), 1235-1242 (2008)
7. N.A. Hibberts, D.J. Simpson, J.E. Bicknell, J.C. Broome, P.R. Hoban, R.N. Clayton, W.E. Farrell, Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin. Cancer Res. 5(8), 2133-2139 (1999)
8. S. Jordan, K. Lidhar, M. Korbonits, D.G. Lowe, A.B. Grossman, Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur. J. Endocrinol. 143(1), R1-R6 (2000)
9. D.J. Simpson, S.J. Frost, J.E. Bicknell, J.C. Broome, A.M. McNicol, R.N. Clayton, W.E. Farrell, Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 22(8), 1149-1154 (2001)
10. H.E. Turner, Z. Nagy, N. Sullivan, M.M. Esiri, J.A. Wass, Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin. Endocrinol. (Oxf) 53(3), 337-344 (2000)
11. V. Chesnokova, S. Zonis, C. Zhou, A. Ben-Shlomo, K. Wawrowsky, Y. Toledano, Y. Tong, K. Kovacs, B. Scheithauer, S. Melmed, Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One 6(3), e17924 (2011)
12. G.M. Pierantoni, P. Finelli, E. Valtorta, D. Giardino, O. Rodeschini, F. Esposito, M. Losa, A. Fusco, L. Larizza, High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. Endocr. Relat. Cancer 12(4), 867-874 (2005)
13. C.S. Moreno, C.O. Evans, X. Zhan, M. Okor, D.M. Desiderio, N.M. Oyesiku, Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 65(22), 10214-10222 (2005)
14. X. Zhang, Y. Zhou, K.R. Mehta, D.C. Danila, S. Scolavino, S.R. Johnson, A. Klibanski, A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J. Clin. Endocrinol. Metab. 88(11), 5119-5126 (2003)
15. J. Zhao, D. Dahle, Y. Zhou, X. Zhang, A. Klibanski, Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J. Clin. Endocrinol. Metab. 90(4), 2179-2186 (2005)
16. K.J. Dudley, K. Revill, R.N. Clayton, W.E. Farrell, Pituitary tumours: all silent on the epigenetics front. J. Mol. Endocrinol. 42(6), 461-468 (2009)
17. D.A. Altomare, J.R. Testa, Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50), 7455-7464 (2005)
18. I. Vivanco, C.L. Sawyers, The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2(7), 489-501 (2002)
19. Y. Lin, X. Jiang, Y. Shen, M. Li, H. Ma, M. Xing, Y. Lu, Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr. Relat. Cancer 16(1), 301-310 (2009)
20. M. Musat, M. Korbonits, B. Kola, N. Borboli, M.R. Hanson, A.M. Nanzer, J. Grigson, S. Jordan, D.G. Morris, M. Gueorguiev, M. Coculescu, S. Basu, A.B. Grossman, Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr. Relat. Cancer 12(2), 423-433 (2005)
21. M. Xu, L. Shorts-Cary, A.J. Knox, B. Kleinsmidt-DeMasters, K. Lillehei, M.E. Wierman, Epidermal growth factor receptor pathway substrate 8 is overexpressed in human pituitary tumors role in proliferation and survival. Endocrinology 150(5), 2064-2071 (2009)
22. D. Dworakowska, E. Wlodek, C.A. Leontiou, S. Igreja, M. Cakir, M. Teng, N. Prodromou, M.I. Goth, S. Grozinsky-Glasberg, M. Gueorguiev, B. Kola, M. Korbonits, A.B. Grossman, Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr. Relat. Cancer 16(4), 1329-1338 (2009)
23. U. Pagotto, T. Arzberger, M. Theodoropoulou, Y. Grubler, C. Pantaloni, W. Saeger, M. Losa, L. Journot, G.K. Stalla, D. Spengler, The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 60(24), 6794-6799 (2000)
24. T.W. Noh, H.J. Jeong, M.K. Lee, T.S. Kim, S.H. Kim, E.J. Lee, Predicting recurrence of nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 94(11), 4406-4413 (2009)
25. M. Theodoropoulou, G.K. Stalla, D. Spengler, ZAC1 target genes and pituitary tumorigenesis. Mol. Cell. Endocrinol. 326(1-2), 60-65 (2010)
26. Y. Yin, W.H. Shen, PTEN: a new guardian of the genome. Oncogene 27(41), 5443-5453 (2008)
27. A. Perren, P. Komminoth, P. Saremaslani, C. Matter, S. Feurer, J.A. Lees, P.U. Heitz, C. Eng, Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. 157(4), 1097-1103 (2000)
28. M.L. Tena-Suck, A. Ortiz-Plata, H.A. de la Vega, Phosphatase and tensin homologue and pituitary tumor-transforming gene in pituitary adenomas. Clinical-pathologic and immunohistochemical analysis. Ann. Diagn. Pathol. 12(4), 275-282 (2008)
29. V. Vasko, M. Saji, E. Hardy, M. Kruhlak, A. Larin, V. Savchenko, M. Miyakawa, O. Isozaki, H. Murakami, T. Tsushima, K.D. Burman, C. De Micco, M.D. Ringel, Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J. Med. Genet. 41(3), 161-170 (2004)
30. A.M. Martelli, I. Faenza, A.M. Billi, L. Manzoli, C. Evangelisti, F. Fala, L. Cocco, Intranuclear 30-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell. Signal. 18(8), 1101-1107 (2006)
31. L.C. Trotman, A. Alimonti, P.P. Scaglioni, J.A. Koutcher, C. Cordon-Cardo, P.P. Pandolfi, Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441(7092), 523-527 (2006)
32. S.S. Chaidarun, M.C. Eggo, M.C. Sheppard, P.M. Stewart, Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology 135(5), 2012-2021 (1994)
33. V.K. LeRiche, S.L. Asa, S. Ezzat, Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J. Clin. Endocrinol. Metab. 81(2), 656-662 (1996)
34. M.L. Jaffrain-Rea, E. Petrangeli, C. Lubrano, G. Minniti, D. Di Stefano, F. Sciarra, L. Frati, G. Tamburrano, G. Cantore, A. Gulino, Epidermal growth factor binding sites in human pituitary macroadenomas. J. Endocrinol. 158(3), 425-433 (1998)
35. A. Rishi, M.C. Sharma, C. Sarkar, D. Jain, M. Singh, A.K. Mahapatra, V.S. Mehta, T.K. Das, A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience. Neurol. India 58(3), 418-423 (2010)
36. M. Theodoropoulou, T. Arzberger, Y. Gruebler, M.L. Jaffrain- Rea, J. Schlegel, L. Schaaf, E. Petrangeli, M. Losa, G.K. Stalla, U. Pagotto, Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J. Endocrinol. 183(2), 385-394 (2004)
37. O. Cooper, G. Vlotides, H. Fukuoka, M.I. Greene, S. Melmed, Expression and function of ErbB receptors and ligands in the pituitary. Endocr. Relat. Cancer 18(6), R197-R211 (2011)
38. P.P. Di Fiore, G. Scita, Eps8 in the midst of GTPases. Int. J. Biochem. Cell Biol. 34(10), 1178-1183 (2002)
39. F. Fazioli, L. Minichiello, V. Matoska, P. Castagnino, T. Miki, W.T. Wong, P.P. Di Fiore, Eps8, a substrate for the epidermal growth factor receptor kinase, enhances EGF-dependent mitogenic signals. EMBO J. 12(10), 3799-3808 (1993)
40. M. Innocenti, E. Frittoli, I. Ponzanelli, J.R. Falck, S.M. Brachmann, P.P. Di Fiore, G. Scita, Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1. J. Cell Biol. 160(1), 17-23 (2003)
41. Y. Greenman, S. Melmed, Diagnosis and management of nonfunctioning pituitary tumors. Annu. Rev. Med. 47, 95-106 (1996)
42. I. Ewing, S. Pedder-Smith, G. Franchi, M. Ruscica, M. Emery, V. Vax, E. Garcia, S. Czirjak, Z. Hanzely, B. Kola, M. Korbonits, A.B. Grossman, A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin. Endocrinol (Oxf) 66(3), 348-352 (2007)
43. T.W. de Bruin, D.J. Kwekkeboom, J.W. Van't Verlaat, J.C. Reubi, E.P. Krenning, S.W. Lamberts, R.J. Croughs, Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J. Clin. Endocrinol. Metab. 75(5), 1310-1317 (1992)
44. M. Gasperi, L. Petrini, R. Pilosu, M. Nardi, A. Marcello, F. Mastio, L. Bartalena, E. Martino, Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. J. Endocrinol. Invest. 16(7), 541-543 (1993)
45. T. Florio, S. Thellung, S. Arena, A. Corsaro, R. Spaziante, G. Gussoni, G. Acuto, M. Giusti, G. Giordano, G. Schettini, Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur. J. Endocrinol. 141(4), 396-408 (1999)
46. H. Padova, H. Rubinfeld, M. Hadani, Z.R. Cohen, D. Nass, J.E. Taylor, M.D. Culler, I. Shimon, Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human nonfunctioning pituitary adenomas. Mol. Cell. Endocrinol. 286(1-2), 214-218 (2008)
47. U. Renner, J. Mojto, M. Lange, O.A. Muller, K. von Werder, G.K. Stalla, Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. Eur. J. Endocrinol. 130(1), 80-91 (1994)
48. M.C. Zatelli, D. Piccin, C. Vignali, F. Tagliati, M.R. Ambrosio, M. Bondanelli, V. Cimino, A. Bianchi, H.A. Schmid, M. Scanarini, A. Pontecorvi, L. De Marinis, G. Maira, E.C. degli Uberti, Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr. Relat. Cancer 14(1), 91-102 (2007)
49. E. Hubina, A.M. Nanzer, M.R. Hanson, E. Ciccarelli, M. Losa, D. Gaia, M. Papotti, M.R. Terreni, S. Khalaf, S. Jordan, S. Czirjak, Z. Hanzely, G.M. Nagy, M.I. Goth, A.B. Grossman, M. Korbonits, Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol. 155(2), 371-379 (2006)
50. M. Theodoropoulou, J. Zhang, S. Laupheimer, M. Paez-Pereda, C. Erneux, T. Florio, U. Pagotto, G.K. Stalla, Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 66(3), 1576-1582 (2006)
51. T. Florio, F. Barbieri, R. Spaziante, G. Zona, L.J. Hofland, P.M. van Koetsveld, R.A. Feelders, G.K. Stalla, M. Theodoropoulou, M.D. Culler, J. Dong, J.E. Taylor, J.P. Moreau, A. Saveanu, G. Gunz, H. Dufour, P. Jaquet, Efficacy of a dopamine- somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr. Relat. Cancer 15(2), 583-596 (2008)
52. E. Peverelli, L. Olgiati, M. Locatelli, P. Magni, M.F. Fustini, G. Frank, G. Mantovani, P. Beck-Peccoz, A. Spada, A. Lania, The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human nonfunctioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett. 288(2), 170-176 (2010)
53. P. Luciani, S. Gelmini, E. Ferrante, A. Lania, S. Benvenuti, S. Baglioni, G. Mantovani, I. Cellai, F. Ammannati, A. Spada, M. Serio, A. Peri, Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 90(11), 6156-6161 (2005)
54. M. Korbonits, E. Carlsen, Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm. Res. 71(Suppl 2), 123-130 (2009)
55. V. Cerovac, J. Monteserin-Garcia, H. Rubinfeld, M. Buchfelder, M. Losa, T. Florio, M. Paez-Pereda, G.K. Stalla, M. Theodoropoulou, The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res. 70(2), 666-674 (2010)
56. M. Breuleux, M. Klopfenstein, C. Stephan, C.A. Doughty, L. Barys, S.M. Maira, D. Kwiatkowski, H.A. Lane, Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/ mTOR inhibition. Mol. Cancer Ther. 8(4), 742-753 (2009)
57. A. Gorshtein, H. Rubinfeld, E. Kendler, M. Theodoropoulou, V. Cerovac, G.K. Stalla, Z.R. Cohen, M. Hadani, I. Shimon, Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GHsecreting pituitary tumor cells in vitro. Endocr. Relat. Cancer 16(3), 1017-1027 (2009)
58. M.C. Zatelli, M. Minoia, C. Filieri, F. Tagliati, M. Buratto, M.R. Ambrosio, M. Lapparelli, M. Scanarini, E.C. Degli Uberti, Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 95(2), 968-976 (2010)
59. K.E. O'Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, D. Smith, H. Lane, F. Hofmann, D.J. Hicklin, D.L. Ludwig, J. Baselga, N. Rosen, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66(3), 1500-1508 (2006)
60. M. Lee, M. Theodoropoulou, J. Graw, F. Roncaroli, M.C. Zatelli, N.S. Pellegata, Levels of p27 sensitize to dual PI3K/mTOR inhibition. Mol. Cancer Ther. 10(8), 1450-1459 (2011)
61. B. Kola, M. Korbonits, S. Diaz-Cano, G. Kaltsas, D.G. Morris, S. Jordan, L. Metherell, M. Powell, S. Czirjak, G. Arnaldi, S. Bustin, M. Boscaro, F. Mantero, A.B. Grossman, Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clin. Endocrinol (Oxf) 59(3), 328-338 (2003)
62. H. Rubinfeld, A. Gorshtein, E. Kendler, A. Kamar, O. Cohen, M. Hadani, I. Shimon IGF-1 induces tumorigenesis in human pituitary tumors-functional blockade of IGF-1 receptor as a novel therapeutic approach in non-functioning tumors, in 2nd ENEA Workshop, Aggressive Pituitary Tumors, Munich, 2011, p. 71
63. F.M. Sirotnak, M.F. Zakowski, V.A. Miller, H.I. Scher, M.G. Kris, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6(12), 4885-4892 (2000)
64. H. Fukuoka, O. Cooper, J. Mizutani, Y. Tong, S.G. Ren, S. Bannykh, S. Melmed, HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol. Endocrinol. 25(1), 92-103 (2011)
65. G. Vlotides, E. Siegel, I. Donangelo, S. Gutman, S.G. Ren, S. Melmed, Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res. 68(15), 6377-6386 (2008)
66. U. Kumar, Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine 40(2), 168-180 (2011)
67. X. Shi, B. Tao, H. He, Q. Sun, C. Fan, L. Bian, W. Zhao, Y.C. Lu, MicroRNAs-based network: a novel therapeutic agent in pituitary adenoma. Med. Hypotheses 78(3), 380-384 (2012)
68. X. Zhan, D.M. Desiderio, Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med. Genomics 3, 13 (2010)